D.E. Shaw & Co
PRLD icon

D.E. Shaw & Co’s Prelude Therapeutics PRLD Stock Holding History

D.E. Shaw & Co’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-49,184
Closed -$152K – 4547
2023
Q3 		$152K Sell
49,184
-6,654
-12% -$25K ﹤0.01% 3802
2023
Q2 		$251K Buy
55,838
+8,589
+18% +$51.3K ﹤0.01% 3664
2023
Q1 		$269K Sell
47,249
-20,756
-31% -$127K ﹤0.01% 3788
2022
Q4 		$411K Sell
68,005
-10,876
-14% -$69.7K ﹤0.01% 3961
2022
Q3 		$521K Sell
78,881
-36,986
-32% -$249K ﹤0.01% 4021
2022
Q2 		$605K Buy
115,867
+92,256
+391% +$470K ﹤0.01% 3990
2022
Q1 		$163K Buy
+23,611
New +$216K ﹤0.01% 4919
2021
Q2 		– Sell
-12,546
Closed -$544K – 4959
2021
Q1 		$544K Buy
+12,546
New +$832K ﹤0.01% 3465

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's PRLD Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 49,184 shares — an estimated $152K sold.

D.E. Shaw & Co first reported a position in PRLD in Q1 2021 and held it in 8 quarters. The position peaked at $605K in Q2 2022. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

  • D.E. Shaw & Co reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 49,184 Prelude Therapeutics shares in Q4 2023, an estimated $152K.
  • D.E. Shaw & Co first reported a position in Prelude Therapeutics in Q1 2021 and held it in 8 quarters.
  • D.E. Shaw & Co's Prelude Therapeutics position peaked at $605K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.